|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-25
|
|
pubmed:abstractText |
In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1610-0387
|
|
pubmed:author |
pubmed-author:AugustinMatthiasM,
pubmed-author:BoehnckeWolf-HenningWH,
pubmed-author:KlausJoachimJ,
pubmed-author:MrowietzUlrichU,
pubmed-author:NastAlexanderA,
pubmed-author:OckenfelsHans-MichaelHM,
pubmed-author:PhilippSandraS,
pubmed-author:ReichKristianK,
pubmed-author:RosenbachThomasT,
pubmed-author:RzanyBertholdB,
pubmed-author:SchlaegerMartinM,
pubmed-author:SebastianMichaelM,
pubmed-author:SterryWolframW,
pubmed-author:StreitVolkerV,
pubmed-author:WeisenseelPeterP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
65-6
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
|
|
pubmed:affiliation |
Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité Universitätsmedizin Berlin, Campus Charité Mitte, Berlin. alexander.nast@charite.de
|
|
pubmed:publicationType |
Journal Article,
Practice Guideline
|
